News & Updates

First-line rucaparib maintenance therapy extends progression-free survival (PFS) in patients with ovarian, fallopian tube, or primary peritoneal cancer, according to results of the phase III ATHENA-MONO trial presented at the ESMO Gynaecological Cancers Conference 2022.

In the phase III STRATUM* trial, the investigational PDE4** inhibitor roflumilast improved multiple symptoms of moderate-to-severe seborrheic dermatitis (SD).

In patients with unresectable RAS and BRAF wildtype metastatic colorectal cancer (mCRC), a modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN*) treatment strategy in the first-line setting did not improve objective response rate (ORR) compared with FOLFOX plus panitumumab (mFOLFOX6/PAN**), results of the phase III TRIPLETE study showed.

Boosting with an mRNA vaccine yields significant protection against severe COVID-19 and may keep people out of the hospital for up to 6 months, as shown in a Singapore study.

In patients with ST‐segment–elevation myocardial infarction (STEMI), treatment with nicorandil prior to undergoing primary percutaneous coronary intervention (PCI) may result in improved myocardial perfusion grade, increased left ventricular ejection fraction, and reduced myocardial infarct size, according to data from the CHANGE* study.

Early treatment with single- or double-dose ivermectin is no better than placebo in avoiding progression to hospitalization and in improving symptoms in mild COVID-19, results of a study have shown.